In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Disregards EPO’s Opinion On Everolimus Patent

Executive Summary

An EPO opposition finding that a patent is invalid has not stopped a UK court from issuing an injunction against Dr Reddy’s generic everolimus on the grounds that the same patent is infringed.

You may also be interested in...



Everolimus SPC Expiries May Not Be End Of The Story

Novartis' everolimus oncology brand, Afinitor, and AstraZeneca's dapagliflozin-based Farxiga diabetes treatment are the focus of January's review of expiring intellectual-property rights, based on IQVIA's Ark Patent Intelligence Database.

Breckenridge, Endo and Hikma’s Advantage On Everolimus Is Snatched Away On Appeal

A US Court of Appeals issues a precedential opinion concerning patent terms affected by a change in law by Congress in the mid-90s, in a ruling on Novartis’ everolimus compound patent shielding the originator’s Afinitor and Zortress brands.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel